Citations

Clear

2429 citation(s) found for "Shah, SS".

Inhibition of sphingosine 1-phosphate signaling ameliorates murine nonalcoholic steatohepatitis
Mauer, Amy S. , Hirsova, Petra , Maiers, Jessica L. , Shah, Vijay H. , Malhi, Harmeet , Hirsova, Petra

Mayo Clinic

American Journal of Physiology-Gastrointestinal and Liver Physiology | December 30, 2016 | Volume: 312 | Issue: 3 | Pages: G300-G313

10.1152/ajpgi.00222.2016 | PMID 28039158 Get It

Nonalcoholic steatohepatitis (NASH) is a lipotoxic disorder, wherein proinflammatory lipids, such as ceramide and its derivative sphingosine 1-phosphate (S1P), contribute to macrophage-associated liver inflammation. For example, we have previously demonstrated a role for S1P in steatotic hepatocyte-derived S1P-enriched extracellular vesicles in macrophage chemotaxis in vitro. Therefore, we hypothesized that FTY720, an S1P antagonist, would ameliorate NASH by inhibiting proinflammatory monocyte chemotaxis. To test our hypothesis, NASH was established in C57BL/6 male mice by feeding a diet high in fructose, saturated fat, and cholesterol for 22 wk. Then mice received daily intraperitoneal injections of FTY720 for 2 wk before analysis of liver injury, inflammation, and fibrosis. FTY720-treated mice with NASH demonstrated improved liver histology with a significant reduction in hepatocyte ballooning and inflammatory foci. Hepatomegaly was reversed, and liver triglycerides were reduced following FTY720 administration to mice with NASH. Correspondingly, serum ALT levels, hepatic inflammatory macrophage accumulation, and the expression of Ly6C in recruited myeloid cells was reduced in FTY720-treated mice. Hepatic collagen accumulation and expression of α-smooth muscle actin were significantly lowered as well. Body composition, energy consumption and utilization, and hepatic sphingolipid composition remained unchanged following FTY720 administration. FTY720 ameliorates murine nonalcoholic steatohepatitis. Reduction in liver injury and inflammation is associated with a reduction in hepatic macrophage accumulation, likely due to dampened recruitment of circulating myeloid cells into the liver. Nonalcoholic steatohepatitis may be a novel indication for the therapeutic use of FTY720. NEW & NOTEWORTHY There are no approved pharmacologic therapies for nonalcoholic steatohepatitis (NASH), the leading cause of chronic liver disease worldwide. This study describes the use of FTY720, a novel small molecule, for the amelioration of NASH in a mouse model. We demonstrate that 2-wk administration of FTY720 to mice with NASH led to a reduction in liver injury, inflammation, and fibrosis. These data provide a preclinical rationale for studying this drug in human NASH.
Transcriptional Induction of Periostin by a Sulfatase 2–TGFβ1–SMAD Signaling Axis Mediates Tumor Angiogenesis in Hepatocellular Carcinoma
Chen, Gang , Nakamura, Ikuo , Dhanasekaran, Renumathy , Iguchi, Eriko , Tolosa, Ezequiel J. , Romecín, Paola , Vera, Renzo E., Almada, Luciana L. , Miamen, Alexander G., Chaiteerakij, Roongruedee , Zhou, Mengtao , Moser, Catherine D., Han, Shaoshan , Hu, Chunling , Banini, Bubu A. , Oseini, Abdul M., Fang, Yong , Yang, Dongye , Shaleh, Hassan M., Wang, Shaoqing , Wu, Dehai, Song, Tao , Lee, Ju‐Seog , Thorgeirsson, Snorri S., Chevet, Éric , Shah, Vijay H. , Fernández-Zapico, Martín E. , Roberts, Lewis R. , Romecin, Paola A, Asiedu, Michael K. , Chen, Yichun, Nakamura, Ikuo, Chaiteerakij, Roongruedee , Chen, Yi‐Chun , Roberts, Lewis R , Dhanasekaran, Renumathy , Hu, Chunling , Chen, Gang , Chevet, Eric

Mayo Clinic

Cancer Research | November 21, 2016 | Volume: 77 | Issue: 3 | Pages: 632-645

10.1158/0008-5472.can-15-2556 | PMID 27872089 Get It

Abstract Existing antiangiogenic approaches to treat metastatic hepatocellular carcinoma (HCC) are weakly effectual, prompting further study of tumor angiogenesis in this disease setting. Here, we report a novel role for sulfatase 2 (SULF2) in driving HCC angiogenesis. Sulf2-deficient mice (Sulf2 KO) exhibited resistance to diethylnitrosamine-induced HCC and did not develop metastases like wild-type mice (Sulf2 WT). The smaller and less numerous tumors formed in Sulf2 KO mice exhibited a markedly lower microvascular density. In human HCC cells, SULF2 overexpression increased endothelial proliferation, adhesion, chemotaxis, and tube formation in a paracrine fashion. Mechanistic analyses identified the extracellular matrix protein periostin (POSTN), a ligand of αvβ3/5 integrins, as an effector protein in SULF2-induced angiogenesis. POSTN silencing in HCC cells attenuated SULF2-induced angiogenesis and tumor growth in vivo. The TGFβ1/SMAD pathway was identified as a critical signaling axis between SULF2 and upregulation of POSTN transcription. In clinical HCC specimens, elevated levels of SULF2 correlated with increased microvascular density, POSTN levels, and relatively poorer patient survival. Together, our findings define an important axis controlling angiogenesis in HCC and a mechanistic foundation for rational drug development. Cancer Res; 77(3); 632–45. ©2016 AACR.
The unfolded protein response mediates fibrogenesis and collagen I secretion through regulating TANGO1 in mice
Maiers, Jessica L. , Kostallari, Enis , Mushref, Malek, deAssuncao, Thiago M., Li, Haiyang , Jalan‐Sakrikar, Nidhi , Cao, Sheng , Shah, Vijay H. , Malhi, Harmeet , Li, Haiyang, Huebert, Robert C. , Kostallari, Enis , Sakrikar, Nidhi Jalan

Mayo Clinic

Hepatology | November 5, 2016 | Volume: 65 | Issue: 3 | Pages: 983-998

10.1002/hep.28921 | PMID 28039913 Get It

Fibrogenesis encompasses the deposition of matrix proteins, such as collagen I, by hepatic stellate cells (HSCs) that culminates in cirrhosis. Fibrogenic signals drive transcription of procollagen I, which enters the endoplasmic reticulum (ER), is trafficked through the secretory pathway, and released to generate extracellular matrix. Alternatively, disruption of procollagen I ER export could activate the unfolded protein response (UPR) and drive HSC apoptosis. Using a small interfering RNA screen, we identified Transport and Golgi organization 1 (TANGO1) as a potential participant in collagen I secretion. We investigated the role of TANGO1 in procollagen I secretion in HSCs and liver fibrogenesis. Depletion of TANGO1 in HSCs blocked collagen I secretion without affecting other matrix proteins. Disruption of secretion led to procollagen I retention within the ER, induction of the UPR, and HSC apoptosis. In wild‐type (WT) HSCs, both TANGO1 and the UPR were induced by transforming growth factor β (TGFβ). As the UPR up‐regulates proteins involved in secretion, we studied whether TANGO1 was a target of the UPR. We found that UPR signaling is responsible for up‐regulating TANGO1 in response to TGFβ, and this mechanism is mediated by the transcription factor X‐box binding protein 1 (XBP1). In vivo , murine and human cirrhotic tissue displayed increased TANGO1 messenger RNA levels. Finally, TANGO1 +/– mice displayed less hepatic fibrosis compared to WT mice in two separate murine models: CCl 4 and bile duct ligation. Conclusion : Loss of TANGO1 leads to procollagen I retention in the ER, which promotes UPR‐mediated HSC apoptosis. TANGO1 regulation during HSC activation occurs through a UPR‐dependent mechanism that requires the transcription factor, XBP1. Finally, TANGO1 is critical for fibrogenesis through mediating HSC homeostasis. The work reveals a unique role for TANGO1 and the UPR in facilitating collagen I secretion and fibrogenesis. (H epatology 2017;65:983‐998).
Willingness to Be a Brain Donor
Boise, Linda, Hinton, Ladson , Rosen, Howard J. , Ruhl, Mary C., Albert, Marilyn , Denny, Andrea, Hughes, Travonia, Lingler, Jennifer H. , Morhardt, Darby, Parfitt, Francine, Peterson-Hazan, Susan, Pop, Viorela, Rose, Tara , Shah, Raj C. , Hinton, Ladson , Dodge, Hiroko Hayama , Mattek, Nora , Grill, Joshua D. , Shah, Raj C

Mayo Clinic

Alzheimer Disease & Associated Disorders | October 25, 2016 | Volume: 31 | Issue: 2 | Pages: 135-140

10.1097/wad.0000000000000174 | PMID 27779492 Get It

Introduction: Racial and ethnic groups are under-represented among research subjects who assent to brain donation in Alzheimer disease research studies. There has been little research on this important topic. Although there are some studies that have investigated the barriers to brain donation among African American study volunteers, there is no known research on the factors that influence whether or not Asians or Latinos are willing to donate their brains for research. Methods: African American, Caucasian, Asian, and Latino research volunteers were surveyed at 15 Alzheimer Disease Centers to identify predictors of willingness to assent to brain donation. Results: Positive predictors included older age, Latino ethnicity, understanding of how the brain is used by researchers, and understanding of what participants need to do to ensure that their brain will be donated. Negative predictors included African/African American race, belief that the body should remain whole at burial, and concern that researchers might not be respectful of the body during autopsy. Discussion: The predictive factors identified in this study may be useful for researchers seeking to increase participation of diverse ethnic groups in brain donation.
Observation Status or Inpatient Admission: Impact of Patient Disposition on Outcomes and Utilization Among Emergency Department Patients With Chest Pain
Bellolio, Fernanda , Sangaralingham, Lindsey R. , Schilz, Stephanie R., Noël-Miller, Claire, Lind, Keith, Morin, Pamela, Shah, Nilay D. , Bellolio, M Fernanda, Noseworthy, Peter A. , Hess, Erik P. , Bellolio, M Fernanda

Mayo Clinic

Academic Emergency Medicine | October 14, 2016 | Volume: 24 | Issue: 2 | Pages: 152-160

10.1111/acem.13116 | PMID 27739128 Get It

AbstractObjectivesto compare healthcare utilization including coronary angiography, percutaneous coronary intervention (PCI), rehospitalization, and rate of subsequent acute myocardial infarction (AMI) within 30 days, among patients presenting to the emergency department (ED) with chest pain admitted as short‐term inpatient (≤2 days) versus observation (in‐ED observation units combined with in‐hospital observation).MethodsWe identified adults diagnosed with acute chest pain in the ED from 2010 to 2014 using administrative claims from privately insured and Medicare Advantage. Patients having AMI during the index visit were excluded. One‐to‐one propensity‐score matching and logistic regression were used. Odds ratios (ORs) with 95% confidence intervals (CIs) were reported.ResultsA total of 774,017 chest pain visits were included. After matching, healthcare utilization was lower among observation versus short inpatient, with 10.9% versus 24.4% (OR = 0.38, 95% CI = 0.36 to 0.39) undergoing cardiac catheterization and 1.8% versus 7.6% (OR = 0.23, 95% CI = 0.21 to 0.24) having PCI. The incidence of subsequent AMI within the following 30 days was similar in patients admitted as observation versus short inpatient (0.23% vs. 0.21%; OR = 1.09, 95% CI = 0.84 to 1.42).ConclusionsThere were higher rates of cardiac catheterization and PCI among those admitted as a short inpatient compared to observation, while the incidence of subsequent AMI within 30 days was similar.
Time trends in the health care burden and mortality of acute on chronic liver failure in the United States
Kim, W. Ray , Moriarty, James P. , Shah, Nilay D. , Larson, Joseph J. , Kamath, Patrick S. , Allen, Alina M.

Mayo Clinic

Hepatology | October 7, 2016 | Volume: 64 | Issue: 6 | Pages: 2165-2172

10.1002/hep.28812 | PMID 27696493 Get It

Acute on chronic liver failure (ACLF) is associated with multisystem organ failure and poor prognosis in hospitalized patients with cirrhosis. We aimed to determine time trends in the epidemiology, economic burden, and mortality of ACLF in the United States. The National Inpatient Sample database was queried between 2001 and 2011. ACLF was defined as two or more extrahepatic organ failures in patients with cirrhosis. The primary outcomes were trends in hospitalizations, hospital costs, and inpatient mortality. The number of hospitalizations for cirrhosis in the United States nearly doubled from 371,000 in 2001 to 659,000 in 2011. The prevalence of ACLF among those hospitalizations increased from 1.5% (n = 5,400) to 5% (n = 32,300). The inpatient costs increased 2‐fold for cirrhosis ($4.8 billion to $9.8 billion) and 5‐fold ($320 million to $1.7 billion) for ACLF. In 2011, the cost per hospitalization for ACLF was 3.5‐fold higher than that for cirrhosis ($53,570 versus $15,193). The in‐hospital fatality rates decreased from 65% to 50% for ACLF and from 10% to 7% for cirrhosis. The organ failure trends in ACLF showed an increasing proportion of cardiovascular and cerebral and decreasing proportion of respiratory and renal failure. Age, male sex, and the number and types of organ failure were predictors of death in ACLF. Conclusion: Cirrhosis and ACLF represent a substantial and increasing health and economic burden in the United States; these data highlight an urgent need for research on pathophysiological mechanisms and effective therapy as well as for education of health care providers of its importance in the care of patients with cirrhosis. (H epatology 2016;64:2165‐2172).
Trends in Drug Utilization, Glycemic Control, and Rates of Severe Hypoglycemia, 2006–2013
Ross, Joseph S. , Inzucchi, Silvio E. , Gill, Thomas M. , Shah, Nilay D. , Yao, Xiaoxi , Lipska, Kasia J. , Herrin, Jeph , McCoy, Rozalina G. , Steinman, Michael Alan , Krumholz, Harlan M. , Gill, Thomas M , Ross, Joseph S

Mayo Clinic

Diabetes Care | September 23, 2016 | Volume: 40 | Issue: 4 | Pages: 468-475

10.2337/dc16-0985 | PMID 27659408 Get It

OBJECTIVETo examine temporal trends in utilization of glucose-lowering medications, glycemic control, and rate of severe hypoglycemia among patients with type 2 diabetes (T2DM).RESEARCH DESIGN AND METHODSUsing claims data from 1.66 million privately insured and Medicare Advantage patients with T2DM from 2006 to 2013, we estimated the annual 1) age- and sex-standardized proportion of patients who filled each class of agents; 2) age-, sex-, race-, and region-standardized proportion with hemoglobin A1c (HbA1c) <6%, 6 to <7%, 7 to <8%, 8 to <9%, ≥9%; and 3) age- and sex-standardized rate of severe hypoglycemia among those using medications. Proportions were calculated overall and stratified by age-group (18–44, 45–64, 65–74, and ≥75 years) and number of chronic comorbidities (zero, one, and two or more).RESULTSFrom 2006 to 2013, use increased for metformin (from 47.6 to 53.5%), dipeptidyl peptidase 4 inhibitors (0.5 to 14.9%), and insulin (17.1 to 23.0%) but declined for sulfonylureas (38.8 to 30.8%) and thiazolidinediones (28.5 to 5.6%; all P < 0.001). The proportion of patients with HbA1c <7% declined (from 56.4 to 54.2%; P < 0.001) and with HbA1c ≥9% increased (9.9 to 12.2%; P < 0.001). Glycemic control varied by age and was poor among 23.3% of the youngest and 6.3% of the oldest patients in 2013. The overall rate of severe hypoglycemia remained the same (1.3 per 100 person-years; P = 0.72), declined modestly among the oldest patients (from 2.9 to 2.3; P < 0.001), and remained high among those with two or more comorbidities (3.2 to 3.5; P = 0.36).CONCLUSIONSDuring the recent 8-year period, the use of glucose-lowering drugs has changed dramatically among patients with T2DM. Overall glycemic control has not improved and remains poor among nearly a quarter of the youngest patients. The overall rate of severe hypoglycemia remains largely unchanged.
Inclusion of Hypoglycemia in Clinical Practice Guidelines and Performance Measures in the Care of Patients With Diabetes
Rodríguez‐Gutiérrez, René , Ospina, Naykky Singh , Shah, Nilay D. , Montori, Víctor M. , Group, for the Hypoglycemia as a Quality Measure in Diabetes Study, McCoy, Rozalina G. , Lipska, Kasia J. , Group, for the Hypoglycemia as a Quality Measure in Diabetes Study, Montori, Victor M , Singh Ospina, Naykky

Mayo Clinic

JAMA Internal Medicine | September 21, 2016 | Volume: 176 | Issue: 11 | Pages: 1714

10.1001/jamainternmed.2016.5046 | PMID 27653613 Get It

Extracellular vesicles in liver pathobiology: Small particles with big impact
Hirsova, Petra , Ibrahim, Samar H. , Verma, Vikas , Morton, Leslie A., Shah, Vijay H. , Verma, Vikas K, Malhi, Harmeet , Hirsova, Petra , LaRusso, Nicholas F. , Gores, Gregory J. , Ibrahim, Samar H

Mayo Clinic

Hepatology | September 15, 2016 | Volume: 64 | Issue: 6 | Pages: 2219-2233

10.1002/hep.28814 | PMID 27628960 Get It

Extracellular vesicles (EVs) are nanometer‐sized, membrane‐bound vesicles released by cells into the extracellular milieu. EVs are now recognized to play a critical role in cell‐to‐cell communication. EVs contain important cargo in the form of proteins, lipids, and nucleic acids and serve as vectors for delivering this cargo from donor to acceptor or target cell. EVs are released under both physiologic and pathologic conditions, including liver diseases, and exert a wide range of effects on target cells. This review provides an overview on EV biogenesis, secretion, cargo, and target cell interactions in the context of select liver diseases. Specifically, the diverse roles of EVs in nonalcoholic steatohepatitis, alcoholic liver disease, viral hepatitis, cholangiopathies, and hepatobiliary malignancies are emphasized. Liver diseases often result in an increased release of EVs and/or in different cargo sorting into these EVs. Either of these alterations can drive disease pathogenesis. Given this fact, EVs represent a potential target for therapeutic intervention in liver disorders. Because altered EV composition may reflect the underlying disease condition, circulating EVs can be exploited for diagnostic and prognostic purposes as a liquid biopsy. Furthermore, ex vivo modified or synthesized EVs can be engineered as therapeutic nano‐shuttles. Finally, we highlight areas that merit further investigation relevant to understanding how EVs regulate liver disease pathogenesis. (H epatology 2016;64:2219‐2233).
Mechanisms Underlying the Pathogenesis of Isolated Impaired Glucose Tolerance in Humans
Varghese, Ron T. , Man, Chiara Dalla , Sharma, Anu , Viegas, Iván , Barosa, Cristina , Marques, Catía , Miles, John M., Rizza, Robert A., Jones, John G. , Dalla Man, Chiara, Shah, Mithun V , Miles, John M., Cobelli, Claudio , Vella, Adrian , Dalla Man, Chiara

Mayo Clinic

The Journal of Clinical Endocrinology & Metabolism | September 7, 2016 | Volume: 101 | Issue: 12 | Pages: 4816-4824

10.1210/jc.2016-1998 | PMID 27603902 Get It

Context: Prediabetes is a heterogeneous disorder classified on the basis of fasting glucose concentrations and 2-hour glucose tolerance. Objective: We sought to determine the relative contributions of insulin secretion and action to the pathogenesis of isolated impaired glucose tolerance (IGT). Design: The study consisted of an oral glucose tolerance test and a euglycemic clamp performed in two cohorts matched for anthropometric characteristics and fasting glucose but discordant for glucose tolerance. Setting: An inpatient clinical research unit at an academic medical center. Patients or Other Participants: Twenty-five subjects who had normal fasting glucose (NFG) and normal glucose tolerance (NGT) and 19 NFG/IGT subjects participated in this study. Intervention(s): Subjects underwent a seven-sample oral glucose tolerance test and a 4-hour euglycemic, hyperinsulinemic clamp on separate occasions. Glucose turnover during the clamp was measured using tracers, and endogenous hormone secretion was inhibited by somatostatin. Main Outcome Measures: We sought to determine whether hepatic glucose metabolism, specifically the contribution of gluconeogenesis to endogenous glucose production, differed between subjects with NFG/NGT and those with NFG/IGT. Results: Endogenous glucose production did not differ between groups before or during the clamp. Insulin-stimulated glucose disappearance was lower in NFG/IGT (24.6 ± 2.2 vs 35.0 ± 3.6 μmol/kg/min; P = .03). The disposition index was decreased in NFG/IGT (681 ± 102 vs 2231 ± 413 × 10−14 dL/kg/min2 per pmol/L; P < .001). Conclusions: We conclude that innate defects in the regulation of glycogenolysis and gluconeogenesis do not contribute to NFG/IGT. However, insulin-stimulated glucose disposal is impaired, exacerbating defects in β-cell function.